Genetic heterogeneity of Alzheimer's disease: complexity and advances
- PMID: 17659844
- DOI: 10.1016/j.psyneuen.2007.05.015
Genetic heterogeneity of Alzheimer's disease: complexity and advances
Abstract
Most of what we know about the pathological process of Alzheimer's disease (AD) results from research on the amyloid cascade hypothesis. This hypothesis in turn is derived largely from the characterization of rare disease-causing mutations in three genes, which code for the amyloid precursor protein (APP), presenilin 1 (PS-1) and presenilin 2 (PS-2) and account for most cases of early-onset autosomal dominant familial AD. These genetic findings also suggested that better understanding of the genetic components of AD, even in the late-onset sporadic forms of the disease, might help to identify central pathways of the AD process and lead to the rapid development of active molecules. Twin studies have reinforced the rationale of this approach, for they indicate that more than 50% of the late-onset AD risk may be attributable to genetic factors. The 1993 discovery that the apolipoprotein E4 (ApoE4) allele is genetically associated with increased risk in both sporadic and familial late-onset Alzheimer's disease strongly supports the validity of this genetic approach. Further progress based on this major finding has nonetheless been disappointing and raises questions about it. First, despite intensive researches, the exact role of APOE in the pathophysiological process still remains unknown. Second, the APOE gene is the only gene so far recognized as a consistent genetic determinant of sporadic forms of AD, even though numerous studies have looked for such genes; these disappointing results suggest persistent methodological limitations. However, recent methodologies allowing new strategies may allow important breakthrough.
Similar articles
-
[Genetic factors and a polygenic model of Alzheimer's disease].Genetika. 1999 Nov;35(11):1558-71. Genetika. 1999. PMID: 10624576 Review. Russian.
-
[Genes in Alzheimer's disease].Rev Neurol. 2006 Mar 1-15;42(5):302-5. Rev Neurol. 2006. PMID: 16538594 Review. Spanish.
-
Molecular genetics of Alzheimer's disease: an update.Ann Med. 2008;40(8):562-83. doi: 10.1080/07853890802186905. Ann Med. 2008. PMID: 18608129 Review.
-
[Alzheimer's disease. Present and future role of genetics].Tijdschr Gerontol Geriatr. 2003 Feb;34(1):13-20. Tijdschr Gerontol Geriatr. 2003. PMID: 12629906 Dutch.
-
[Advances in the research on Alzheimer's disease--overview].Rinsho Shinkeigaku. 1997 Dec;37(12):1093-4. Rinsho Shinkeigaku. 1997. PMID: 9577653 Review. Japanese.
Cited by
-
Current biomarkers and treatment strategies in Alzheimer disease: An overview and future perspectives.IBRO Neurosci Rep. 2023 Nov 30;16:8-42. doi: 10.1016/j.ibneur.2023.11.003. eCollection 2024 Jun. IBRO Neurosci Rep. 2023. PMID: 38169888 Free PMC article. Review.
-
Modifiable cardiovascular risk factors and genetics for targeted prevention of dementia.Eur Heart J. 2023 Jul 21;44(28):2526-2543. doi: 10.1093/eurheartj/ehad293. Eur Heart J. 2023. PMID: 37224508 Free PMC article.
-
Step by step: towards a better understanding of the genetic architecture of Alzheimer's disease.Mol Psychiatry. 2023 Jul;28(7):2716-2727. doi: 10.1038/s41380-023-02076-1. Epub 2023 May 2. Mol Psychiatry. 2023. PMID: 37131074 Free PMC article. Review.
-
Maternal High Fat Diet Anticipates the AD-like Phenotype in 3xTg-AD Mice by Epigenetic Dysregulation of Aβ Metabolism.Cells. 2023 Jan 4;12(2):220. doi: 10.3390/cells12020220. Cells. 2023. PMID: 36672155 Free PMC article.
-
Complement C7 is a novel risk gene for Alzheimer's disease in Han Chinese.Natl Sci Rev. 2019 Mar;6(2):257-274. doi: 10.1093/nsr/nwy127. Epub 2018 Nov 5. Natl Sci Rev. 2019. PMID: 31032141 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous